Harihar Pharma Chem Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 2.00 Cr
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.58 Cr
- Revenue Growth 584222.53%
- Profit Growth 50.00%
- Ebitda 2669.98%
- Net Worth -1.17%
- Total Assets 77.22%
About Harihar Pharma Chem
Harihar Pharma Chem Private Limited (HPCPL) is a Private Limited Indian Non-Government Company incorporated in India on 26 December 2019 (Five years and two months 3 days old ). Its registered office is in Vadodara, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹18.58 Cr.
Pyariben Rawal and Prakashchandra Rawaln serve as directors at the Company.
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24299GJ2019PTC111669
- Company No.
111669
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Harihar Pharma Chem?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pyariben Rawal  | Director | 26-Dec-2019 | Current |
| Prakashchandra Rawaln | Director | 26-Dec-2019 | Current |
Financial Performance of Harihar Pharma Chem.
Harihar Pharma Chem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 584222.53% increase. The company also saw a substantial improvement in profitability, with a 50% increase in profit. The company's net worth dipped by a decrease of 1.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Harihar Pharma Chem?
In 2023, Harihar Pharma Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Moksh Healthcare Private LimitedPrakashchandra Rawaln is a mutual person
Charges (Loans)
₹18.58 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 18.58 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Nov 2021 | Others | ₹9.54 Cr | Open |
| 10 Nov 2021 | Others | ₹9.04 Cr | Open |
How Many Employees Work at Harihar Pharma Chem?
Unlock and access historical data on people associated with Harihar Pharma Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Harihar Pharma Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Harihar Pharma Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.